This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Cartesian Therapeutics (RNAC) and Abbott Laboratories (ABT)

Tipranks - Tipranks - Wed Jun 10, 7:24PM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tango Therapeutics (TNGX), Cartesian Therapeutics (RNAC) and Abbott Laboratories (ABT) with bullish sentiments.

Introducing TipRanks MCP for Agents

Tango Therapeutics (TNGX)

Guggenheim analyst Michael Schmidt maintained a Buy rating on Tango Therapeutics yesterday and set a price target of $32.00. The company’s shares closed last Tuesday at $31.56.

According to TipRanks.com, Schmidt is a 5-star analyst with an average return of 27.1% and a 51.9% success rate. Schmidt covers the Healthcare sector, focusing on stocks such as Zentalis Pharmaceuticals, ArriVent BioPharma, Inc., and Monte Rosa Therapeutics. ;'>

Tango Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $38.64, which is a 19.9% upside from current levels. In a report issued on June 8, Wolfe Research also upgraded the stock to Buy with a $35.00 price target.

See the top stocks recommended by analysts >>

Cartesian Therapeutics (RNAC)

In a report released yesterday, Uy Ear from Mizuho Securities reiterated a Buy rating on Cartesian Therapeutics, with a price target of $40.00. The company’s shares closed last Tuesday at $6.85.

According to TipRanks.com, Ear is a 2-star analyst with an average return of 0.0% and a 37.9% success rate. Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, ACADIA Pharmaceuticals, and MBX Biosciences, Inc. ;'>

Currently, the analyst consensus on Cartesian Therapeutics is a Strong Buy with an average price target of $29.75, implying a 324.4% upside from current levels. In a report issued on May 26, Needham also maintained a Buy rating on the stock with a $40.00 price target.

Abbott Laboratories (ABT)

In a report released yesterday, Josh Jennings from TD Cowen maintained a Buy rating on Abbott Laboratories. The company’s shares closed last Tuesday at $91.25.

According to TipRanks.com, Jennings is a 3-star analyst with an average return of 1.3% and a 45.2% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Anteris Technologies Global Corp., Establishment Labs Holdings, and Orchestra BioMed Holdings. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Abbott Laboratories with a $120.06 average price target, implying a 32.3% upside from current levels. In a report issued on May 29, Piper Sandler also maintained a Buy rating on the stock with a $115.00 price target.

Read More on TNGX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).